MD Anderson Cancer Center at Texas Medical Center

Clinical research site in Houston, Texas · 1515 HOLCOMBE BLVD UNIT 428, HOUSTON, TX 77030-4028 · (713) 794-1464 · Website

3.7on Google· View on Google Maps

As of September 2026, 356 paid clinical trials are recruiting at MD Anderson Cancer Center at Texas Medical Center in Houston, Texas. Active studies at this site cover conditions such as Hematopoietic and Lymphoid Cell Neoplasm, Acute Myeloid Leukemia and Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 4, 2026.

New trial at MD Anderson Cancer Center at Texas Medical Center? We'll email you when one opens.

Recruiting clinical trials at MD Anderson Cancer Center at Texas Medical Center (356)

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

for Mesothelioma

22 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05245500·Phase 1·Recruiting·Listed Feb 2022

Apply to this trial

A Phase 1/1b Study of IAM1363 in HER2 Cancers

for HER2 Mutation-Related Tumors

29 locations incl. La Jolla

Sponsor: Iambic Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06253871·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

30 locations incl. Newport Beach

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

for Meningioma

12 locations incl. Birmingham

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT07428616·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

for Advanced Urothelial Cancer

10 locations incl. Duarte

Sponsor: Generate Biomedicines

Sex: All·Age: 18+

Code: NCT07484022·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

for GIST - Gastrointestinal Stromal Tumor

17 locations incl. Los Angeles

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT07406633·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

for HER2 Expressing Solid Tumors

11 locations incl. Los Angeles

Sponsor: Vironexis Biotherapeutics Inc.

Sex: All·Age: 18+

Code: NCT07192432·Phase 1, Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

for Invasive Mold Infections

19 locations incl. Birmingham

Sponsor: Basilea Pharmaceutica

Sex: All·Age: 18+

Code: NCT06925321·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

14 locations incl. San Francisco

Sponsor: Debiopharm International SA

Sex: All·Age: 12+

Code: NCT04855656·Phase 1·Recruiting·Listed Apr 2021

Apply to this trial

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

for Ewing Sarcoma

18 locations incl. Beverly Hills

Sponsor: Inhibrx Biosciences, Inc

Sex: All·Age: 12 - 85

Code: NCT03715933·Phase 1·Recruiting·Listed Oct 2018

Apply to this trial

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

for Pemphigus Vulgaris

10 locations incl. Redwood City

Sponsor: Cabaletta Bio

Sex: All·Age: 18+

Code: NCT04422912·Phase 1, Phase 2·Recruiting·Listed Jun 2020

Apply to this trial

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

for Endometrial Cancer

12 locations incl. Phoenix

Sponsor: Iovance Biotherapeutics, Inc.

Sex: Female·Age: 18 - 70

Code: NCT06481592·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for Advanced Solid Tumor

13 locations incl. Los Angeles

Sponsor: Volastra Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05902988·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

for Hematologic Neoplasms

6 locations incl. Indianapolis

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07572006·Phase 1·Recruiting·Listed May 2026

Apply to this trial

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

for Non-Small Cell Lung Cancer

5 locations incl. La Jolla

Sponsor: Fate Therapeutics

Sex: All·Age: 18+

Code: NCT07216105·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

for Advanced HR+/HER2- Breast Cancer

8 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06726148·Phase 1, Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

for Low-grade Upper Tract Urothelial Carcinoma

9 locations incl. Scottsdale

Sponsor: Ferring Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06668493·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

for Tumor Skin

8 locations incl. Los Angeles

Sponsor: Obsidian Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06060613·Phase 1, Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Study of APR-1051 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

5 locations incl. Houston

Sponsor: Aprea Therapeutics

Sex: All·Age: 18+

Code: NCT06260514·Phase 1·Recruiting·Listed Feb 2024

Apply to this trial

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

8 locations incl. Jacksonville

Sponsor: Vividion Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05954312·Phase 1·Recruiting·Listed Jul 2023

Apply to this trial

Comprehensive Assessment of Cancer Theranostic Response

for Prostate Cancer

2 locations incl. New York

Sponsor: AIQ Solutions

Sex: Male·Age: 18+

Code: NCT06815354·Recruiting·Listed Feb 2025

Apply to this trial

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

for Glioblastoma, IDH-wildtype

7 locations incl. Detroit

Sponsor: Orbus Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05879367·Phase 1·Recruiting·Listed May 2023

Apply to this trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

for Melanoma

9 locations incl. San Francisco

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Sex: All·Age: 18+

Code: NCT06281678·Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

for Relapsed Adult AML

1 location in Houston

Sponsor: Pacylex Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06613217·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

for Clear Cell Renal Cell Carcinoma

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18 - 70

Code: NCT07564232·Phase 1·Recruiting·Listed May 2026

Apply to this trial

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

for T-cell Acute Lymphoblastic Leukemia

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 12 - 30

Code: NCT07513129·Phase 1·Recruiting·Listed Apr 2026

Apply to this trial

Baseline Anxiety Trajectories in Pediatric Radiation Therapy Observational Cohort

for Anxiety

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 2 - 12

Code: NCT07575815·Recruiting·Listed May 2026

Apply to this trial

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

for AML

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07508982·Phase 1, Phase 2·Recruiting·Listed Apr 2026

Apply to this trial

Trial of Spiritual Care Interventions for Patients With Cancer

for Advanced Cancer

3 locations incl. New York

Sponsor: Weill Medical College of Cornell University

Sex: All·Age: 18+

Code: NCT07408310·Recruiting·Listed Feb 2026

Apply to this trial

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

for Anatomic Stage I Breast Cancer AJCC v8

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07407920·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Radiofrequency Ablation For Recurrent Parathyroid Carcinoma

for Recurrent Parathyroid Carcinoma

1 location in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07475780·Recruiting·Listed Mar 2026

Apply to this trial

A Study of Revumenib and Mezigdomide in People With Leukemia

for Leukemia

10 locations incl. Duarte

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 12+

Code: NCT07356154·Phase 1, Phase 2·Recruiting·Listed Jan 2026

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1089 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

for Cervical Carcinoma

18 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 25+·Accepts healthy volunteers

Code: NCT07281430·Recruiting·Listed Dec 2025

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

925 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

448 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015

Apply to this trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for Anatomic Stage I Breast Cancer AJCC v8

596 locations incl. Phoenix

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

614 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069·Recruiting·Listed Apr 2022

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

779 locations incl. Fairhope

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for Metastatic Small Intestinal Adenocarcinoma

399 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04205968·Phase 2·Recruiting·Listed Dec 2019

Apply to this trial

Showing the 40 most relevant of 356 recruiting trials at this site. Browse all with filters →

Get new-trial alerts for MD Anderson Cancer Center at Texas Medical Center

We'll email you whenever a new clinical trial starts recruiting at this research site in Houston, TX. Unsubscribe anytime.

More research sites in Houston

MD Anderson Cancer Center (406 trials)
M D Anderson Cancer Center (251 trials)
Baylor College of Medicine (192 trials)
The University of Texas Health Science Center at Houston (183 trials)
The University of Texas MD Anderson Cancer Center (132 trials)
Houston Methodist Hospital (130 trials)
Texas Children's Hospital (110 trials)
The University of Texas M. D. Anderson Cancer Center (86 trials)
University of Texas MD Anderson Cancer Center (83 trials)
UT MD Anderson Cancer Center (74 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Houston, TX · Texas clinical trials